Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Retatrutide offers a modern solution that can complement a personalized wellness program, making it easier to stay committed to long-term goals
Food and Drug Administration (FDA) in June 2019 under the brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women
Reference medical guidelines that support semaglutide use in your situation
Patients with favorable genetic profiles often see appetite effects by day 57 and measurable weight loss by week 2
Clinical trials have shown that patients taking Wegovy (semaglutide) at the maintenance dose of 2.4mg lost an average of 15% to 21% of their body weight over 68 weeks when combined with diet and exercise
Managing gastrointestinal adverse events during GLP-1 receptor agonist therapy
US$ 27.76
US$ 22.21
US$ 29.55
US$ 28.77
US$ 23.50
US$ 22.14
US$ 24.93
